Claritin-D “Staying Tough” Behind The Counter With Pseudoephedrine
This article was originally published in The Tan Sheet
Executive Summary
New ads for Schering-Plough's Claritin-D aim to position the manufacturer as taking a stand by declining to join the ranks of OTC manufacturers who are reformulating their pseudoephedrine-containing products with phenylephrine
You may also be interested in...
Phenylephrine “Not Significantly Different From” Placebo – Schering Study
Schering-Plough released a study on phenylephrine's efficacy as compared to pseudoephedrine and placebo Oct. 31 that "raises even more questions" about the drug, according to Rep. Henry Waxman (D-Calif.)
Phenylephrine “Not Significantly Different From” Placebo – Schering Study
Schering-Plough released a study on phenylephrine's efficacy as compared to pseudoephedrine and placebo Oct. 31 that "raises even more questions" about the drug, according to Rep. Henry Waxman (D-Calif.)
Phenylephrine “Not Significantly Different From” Placebo – Schering Study
Schering-Plough released a study on phenylephrine's efficacy as compared to pseudoephedrine and placebo Oct. 31 that "raises even more questions" about the drug, according to Rep. Henry Waxman (D-Calif.)